Bopindolol: Pharmacological Basis and Clinical Implications

Takafumi Nagatomo, Yoshiaki Hosohata, Toshio Ohnuki, Takashi Nakamura, Kaoru Hattori, Jun Suzuki, and Masaji Ishiguro*

Department of Pharmacology, Niigata College of Pharmacy, Niigata, Japan; *Suntory Institute for Bioorganic Research, Osaka, Japan

Key Words: Bopindolol — β-Adrenoceptor antagonists — β-Adrenoceptors — Cardiovascular diseases — Hypertension.

ABSTRACT

Bopindolol, a non-selective antagonist of β₁- and β₂-adrenoceptors (ARs), has been found by pharmacological, molecular biological techniques and molecular modeling to have several unique properties. Bopindolol produces sustained blockade of β₁- and β₂-ARs, has intrinsic sympathomimetic as well as membrane stabilizing actions, inhibits renin secretion, and interacts with 5-HT receptors. Also, our recent molecular modeling studies identified possible interaction sites between bopindolol and β-AR subtypes. The reviewed studies support our findings that bopindolol is non-selective for β₁- and β₂-ARs, has low affinity for β₃-AR subtype and has pharmacological properties that are likely to be beneficial in the treatment of cardiovascular diseases.